| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1229111a198f86af4112ecd730b55cd9 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-185
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-1136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-48 |
| filingDate |
2019-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_edc739763521a968d50dcd52b92c179a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a76b378b07333db026e30701a7b2da46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37626e253b33dc866b70d775b28dbd29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7004358bbbf93cf86c71096a5b54794d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_954ad1156180097d6e030ea3c862100c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1268bb553a9477bc1ae5d5c07cc072c9 |
| publicationDate |
2020-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020031893-A1 |
| titleOfInvention |
Novel prongf mutants and uses thereof in the production of beta-ngf |
| abstract |
The present invention relates to a proNGF mutant and to uses thereof, in particular the use of a proNGF mutant for producing human beta-NGF. The present invention discloses a method of preparing a biologically active human beta-NGF from an inactive insoluble proNGF mutant. A proNGF mutant of the invention is substituted by amino acid but not Arg or Lys at the native protease cleavage site R1SK3R4 at least at positions R1 and K3 corresponding to positions 101 and 103 of the human wildtype proNGF sequence. |
| priorityDate |
2011-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |